[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594133":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"GROUP A",null,"Natural estrogen (estradiol or valerate estradiol) administered transdermically",{"label":13,"type":10,"description":14,"interventionNames":10},"GROUP B","Natural estrogen administered orally",{"label":16,"type":10,"description":17,"interventionNames":10},"GROUP C","Etinil-estradiol administered orally",{"label":19,"type":10,"description":20,"interventionNames":10},"GROUP D","No therapy",[22],{"name":23,"affiliation":5,"role":24},"Maria C Meriggiola, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","0512144394","+39","cristina.meriggiola@unibo.it",[32],{"facility":33,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"IRCCS Azienda Ospedaliero -Univeristaria di Bologna","RECRUITING","Bologna","40138","Italy","IT",{"type":40,"coordinates":41},"Point",[42,43],11.33875,44.49381,{"lat":43,"lon":42},[46],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100594133","retrospective-observational-evaluation-of-the-bone-mineral-density-outcome-in-young-women-with-amenorrhea-100594133",false,"NCT07015476","Retrospective Observational Evaluation of the Bone Mineral Density Outcome in Young Women With Amenorrhea","Retrospective Observational Evaluation of the Bone Mineral Density Outcome of Different Oestrogen Therapy Regimens in Young Women With Amenorrhea","Inclusion criteria:\n\n* Patients who have presented themselves to the O.U. of Gynecology and Human Reproduction Pathophysiology in the period from 2011 to 2020 with amenorrhea over 6 months, and aged between 15 and 39 years at the time of the visit.\n* Patients who have reached the age of 18 at the time of surgery.\n* Patients for whom informed consent has been obtained.\n\nExclusion criteria: No exclusion criteria are provided.","FEMALE","15 Years","39 Years",{"count":60,"type":61},180,"ESTIMATED","OBSERVATIONAL","The study aims to evaluate the outcomes of different estrogen therapy regimens in patients with amenorrhea who face prolonged periods of hypoestrogenism.\n\nThe primary objective is to compare the outcomes on bone mass of different therapeutic regimens and identify more favorable. For this purpose, densitometry parameters such as BMD, T-score and Z-score at the level of the lumbar spine, femur and entire skeleton will be considered, comparing a bone densitometry (DXA technique, Dual X-ray Absorptiometry) Baseline with one carried out after at least one year of therapy. The secondary objective of the study is to assess other systemic\u002Fmetabolic implications of the different therapies.",[65],"Amenorrhea",[65,67,68],"Bone Mass","Estrogen Therapy","2025-06-03",{"date":71,"type":72},"2025-06-11","ACTUAL",{"date":74,"type":72},"2020-11-09",{"date":76,"type":61},"2026-11",{"name":5,"class":6},1]